These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 33120755)

  • 1. Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast: A case report.
    Zhang Y; Liu C; Zheng C; Ren Q; Wang Q; Gao X; He Y; Wu J; Chen G; Li X; Ma Z
    Medicine (Baltimore); 2020 Oct; 99(43):e22652. PubMed ID: 33120755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy.
    Liu X; Qu H; Cao W; Wang Y; Ma Z; Li F; Wang H
    Endocr J; 2013; 60(6):819-28. PubMed ID: 23714650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of premenopausal stage IV breast cancer responding to neoadjuvant endocrine therapy after chemotherapy with FEC].
    Konishi K; Hasegawa N; Kaneko H; Iimura Y; Shoji Y; Kawabata M
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):111-3. PubMed ID: 20087042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant endocrine therapy in breast cancer.
    Beresford MJ; Ravichandran D; Makris A
    Cancer Treat Rev; 2007 Feb; 33(1):48-57. PubMed ID: 17134840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.
    Dellapasqua S; Gray KP; Munzone E; Rubino D; Gianni L; Johansson H; Viale G; Ribi K; Bernhard J; Kammler R; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Regan MM; Goldhirsch A; Colleoni M;
    J Clin Oncol; 2019 Feb; 37(5):386-395. PubMed ID: 30589600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
    Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy].
    Baba S; Oji Y; Teramoto M; Kawabata K; Saito A
    Gan To Kagaku Ryoho; 2009 Nov; 36(11):1905-6. PubMed ID: 19920398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
    Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
    J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
    Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
    Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neoadjuvant endocrine therapy for locally advanced breast cancer].
    Viola G; Sergi D; Conti F; Lopez M
    Clin Ter; 2007; 158(5):441-52. PubMed ID: 18062352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and treatment response of solid neuroendocrine breast carcinoma to adjuvant chemotherapy and endocrine therapy.
    Zhu Y; Li Q; Gao J; He Z; Sun R; Shen G; Zhang H; Xia W; Xu J
    Breast J; 2013; 19(4):382-7. PubMed ID: 23721399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells.
    Ueno T; Masuda N; Kamigaki S; Morimoto T; Akiyama F; Kurosumi M; Tsuda H; Mikami Y; Tanaka S; Morita S; Toi M
    Cancer Med; 2018 Jun; 7(6):2442-2451. PubMed ID: 29733541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
    J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
    van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
    Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.
    Gazet JC; Ford HT; Gray R; McConkey C; Sutcliffe R; Quilliam J; Makinde V; Lowndes S; Coombes RC
    Ann Oncol; 2001 May; 12(5):685-91. PubMed ID: 11432629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of goserelin in combination with endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for hormone receptor: a retrospective matched case-control study.
    Wu S; Li Q; Zhu Y; Sun J; Li F; Lin H; Guan X; He Z
    Cancer Biother Radiopharm; 2013 Dec; 28(10):697-702. PubMed ID: 23806020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study.
    Aihara T; Munakata S; Morino H; Takatsuka Y
    J Surg Oncol; 2004 Feb; 85(2):77-81. PubMed ID: 14755507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in the endocrine management of breast cancer.
    Mouridsen HT; Rose C; Brodie AH; Smith IE
    Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.